.png)
Herantis Pharma
Herantis Pharma - Early CDNF topline results in Parkinson’s (ABG Sundal Collier)
2020-02-25 08:59
Topline results from Phase 1-2 CDNF trial
Promising early data with further readouts to come
Webcast on Friday 28th February for more details
Positive safety and tolerability profile of CDNF in Parkinson’sHerantis announced today the topline results from the ongoing Phase 1-2 clinical trial examining Herantis’ proprietary neuroprotective factor and novel drug candidate, CDNF, in patients with Parkinson’s disease. The company announced that the study met its primary endpoint of safety and tolerability. More importantly, the company also observed promising signals in some patients, for instance in dopamine transporter PET imaging, which is an indirect measure of the dopaminergic function.
Promising early data with further readouts to come
As discussed in our initiation report, the phase 1-2 study (n=17) should primarily be viewed as a safety and tolerability study to investigate both the effects of the drug and the drug delivery system. The early efficacy signal with dopamine transporter PET imaging is encouraging in our view. However, without any more details at this stage and only 6 months of data it is hard to draw any final conclusions but it is promising that all patients who completed the first part of the trial volunteered to participate in the extension study. We expect the next set of results, including details on the exploratory endpoints, in Q3’20. Herantis also announced today the next step for the CDNF program with the planning of a Phase 2 study with a longer treatment period that will assess the efficacy of CDNF in earlier-stage, well-characterized Parkinson’s patients. Early stage patients are hypothesized to have better response to treatments since fewer dopamine producing neurons have lost their ability to produce dopamine. Patient enrolment is expected to start in 2021.
Herantis will hold a conference call on Friday 28th February
We expect more flavour on the results on Friday 28th February at 10:00 am CET when Herantis will hold a conference call to d
...
- Läs mer på Introduce
Läsaren av innehållet kan anta att ABG Sundal Collier har erhållit eller kommer att erhålla betalning för utförandet av finansiella företagstjänster från bolaget. Ersättningen är på förhand avtalad och är inte beroende av innehållet.
info@introduce.se (Introduce.se)
ABG Sundal Collier - Introduce.se